发明名称 PROSTATE CANCER BIOMARKERS
摘要 <p>The present disclosure relates to a method of determining whether a mammalian subject belongs to a first or a second group of subjects, wherein the risk of having a prostate cancer, such as an aggressive prostate cancer, is higher in the first group than in the second group. The method comprises the steps of: a) evaluating an amount of unglycosylated CNDP1 protein in a sample derived from blood, semen or urine from the subject and determining a sample value corresponding to the evaluated amount; b) comparing the sample value with a predetermined reference value; and if the sample value is lower than or equal to the reference value, c1 ) concluding that the subject belongs to the first group; and if the sample value is higher than the reference value, c2) concluding that the subject belongs to the second group. Further, the present disclosure relates to a similar method based on the protein HCRTR1 as well as corresponding uses and means useful when carrying out the methods.</p>
申请公布号 WO2011149402(A2) 申请公布日期 2011.12.01
申请号 WO2011SE00102 申请日期 2011.05.27
申请人 ATLAS ANTIBODIES AB;SCHWENK, JOCHEN;NILSSON, PETER;UHLEN, MATHIAS 发明人 SCHWENK, JOCHEN;NILSSON, PETER;UHLEN, MATHIAS
分类号 G01N33/574;C07K16/40 主分类号 G01N33/574
代理机构 代理人
主权项
地址